Blog

CLASSIC LIST

AD.jpg

March 5, 2021 Clinical Trials

Arlington Research Center is looking for children and adults, aged 6 years and up who have eczema, to participate in a clinical research study evaluating an investigational cream. This study includes up to 5 visits for 2 months.

Studies for youth and adults. Must have a history of atopic for at least 3 months for youth 6-17 years of age, and for at least 6 months for adults 18 years and older. Study patients previously on the ARQ-151 are excluded.

How can you participate?

Inquire about how you can participate in this study today.

TO LEARN MORE ABOUT THE INTEGUMENT STUDY, CONTACT:
studies@acderm.com or call 817-795-7546 ext. 339


Vitiligo.jpg

March 5, 2021 Clinical Trials

NEW study for adults 18 and older. Topical cream and at-home phototherapy system. Must have facial vitiligo. Subjects with vitiligo on the hands, forearms, or elbows may treat areas in addition to the face with the cream. Begins in mid-March.

How can you participate?

Inquire about how you can participate in this study today.

TO LEARN MORE ABOUT THE VITILIGO STUDY, CONTACT:
studies@acderm.com or call 817-795-7546 ext. 339


Wart.jpg

COMING SOON!!

New study for ages 2 years old and up. No more than 6 warts present at screening/baseline visit. Warts must have been present for 4 weeks.

Call 817-795-7546 or email studies@acderm.com if you think you would like to participate in this study.


AdultPsoriasis.jpg

July 29, 2020 Clinical Trials

Adults 18-75 years old may qualify for this 12-week (or potentially longer) study. 6 months of clinical diagnosis is required. This study is for patients that have a skin condition known as Plaque Psoriasis (“Psoriasis”).

The purpose of this study is to understand how well tapinarof 1% cream works in treating your Psoriasis and to get more information about tapinarof 1% cream’s safety. In this study about 500 people in the United States and Canada will be taking part. Tapinarof is an investigational cream.

There will be 2 (two) groups in the study. One group will get the tapinarof 1% cream, the other group will get the vehicle cream. A computer will put you as a study participant to one of the groups by chance (like a roll of the dice). Neither you nor the study doctor can choose a group. You have a 66.6% chance of being placed in the tapinarof 1% cream group and a 33.3% chance of being placed in the vehicle cream group.

After the screening study visits, if you qualify to take part in the study, you will be scheduled to see the study doctor at their office on Day 1 (Baseline), Week 2, Week 4, Week 8, Week 12, and Week 16. You might have to visit the study doctor at other times (unscheduled visits) if your Psoriasis gets worse. During the visits, you will have tests, and answer questions about any changes to your health.

At the Week 12 visit, if you qualify, you can choose to take part in a longer study (long-term) that lasts 40 weeks (about 9 months). All participants in the long-term study will use tapinarof 1% cream (open-label). You will have to sign an Informed Consent Form to participate in the open-label long-term study.

Call 817-795-7546 or email studies@acderm.com if you think you would like to participate in this study.


SeborrheicDermatitis.jpg

July 28, 2020 Clinical Trials

Another new topical study for patients 12 years and older. This trial runs 13 weeks.

Seborrheic dermatitis is a common skin condition that often affects the scalp, causing symptoms that range from dry flakes (dandruff) to yellow, greasy scales with reddened skin. Seborrheic dermatitis can also affect other oily areas of the body, such as the face, upper chest, and back.

If you are 12 or older and have seborrheic dermatitis on your scalp, face, or body, you may qualify to participate in a new clinical research study. The study is for an investigational topical foam, applied once daily for seborrheic dermatitis.

As part of the study participants will be randomly assigned (by chance) to use either the active investigational foam (2 in 3 chance) or an inactive foam (1 in 3 chance). The inactive foam looks just like the investigational foam, but has no active ingredient. Neither you nor your doctor will know which foam you receive. This is a common technique in clinical studies, as it helps researchers understand the effects of the investigational medication.

Call 817-795-7546 or email studies@acderm.com if you think you would like to participate in this study.


Copyright © 2020 . All rights reserved. Website Designed by Gott Marketing